Sugammadex (Bridion)

The use of sugammadex (Bridion) in general anesthesia cases can vary depending on several factors, including the specific patient population, the type of surgery, and institutional guidelines. Here are some insights from the available literature:

Frequency of Use

  • In a retrospective analysis, sugammadex was used in about 3% of the total cases (128 out of 4,282) for “preventive” use, primarily in patients with increased risk of complications with neostigmine reversal, such as elderly patients, those with morbid obesity, or those with various comorbidities[5].
  • In another study involving severe burn patients, sugammadex was utilized in 28.7% of the total surgeries (649 out of 2,259 surgeries)[3].

Specific Indications

  • Sugammadex is often reserved for cases where rapid and reliable reversal of neuromuscular blockade is critical, such as in patients with difficult airway management, those requiring high-dose rocuronium for rapid sequence induction, or in situations where neostigmine is contraindicated or less effective[5][6].

General Anesthesia Settings

  • While it is not universally used in all general anesthesia cases, sugammadex is increasingly recognized for its benefits in reducing residual neuromuscular blockade, postoperative pulmonary complications, and postoperative nausea and vomiting (PONV)[2][3][4].

Cost and Availability

  • The decision to use sugammadex can also be influenced by its higher cost compared to traditional reversal agents like neostigmine. Despite its clinical benefits, cost concerns remain a significant barrier to its widespread adoption[4][5].

In summary, while sugammadex is not used in every general anesthesia case, it is employed in a significant proportion of cases where its specific benefits are deemed necessary, particularly in high-risk patients or complex surgical scenarios. The frequency of its use can range from a few percent in general populations to nearly 30% in specific high-risk groups.

Citations:
[1] https://pubmed.ncbi.nlm.nih.gov/19441874/
[2] https://www.ncbi.nlm.nih.gov/books/NBK470263/
[3] https://www.nature.com/articles/s41598-024-51171-y
[4] https://www.nature.com/articles/s41598-023-32730-1
[5] https://www.dovepress.com/sugammadex-for-reversal-of-neuromuscular-blockade-a-retrospective-anal-peer-reviewed-fulltext-article-CEOR
[6] https://bmcanesthesiol.biomedcentral.com/articles/10.1186/s12871-019-0887-3
[7] https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.1072711/full
[8] https://pubs.asahq.org/anesthesiology/article/132/6/1371/109074/Sugammadex-versus-Neostigmine-for-Reversal-of